Dominant-negative p53 mutations selected in yeast hit cancer hot spots.
Clinically important mutant p53 proteins may be tumorigenic through a dominant-negative mechanism or due to a gain-of-function. Examples for both hypotheses have been described; however, it remains unclear to what extent they apply to TP53 mutations in general. Here it is shown that the mutational spectrum of dominant-negative p53 mutants selected in a novel yeast assay correlates tightly with p53 mutations in cancer. Two classes of dominant-negative mutations are described; the more dominant one affects codons that are essential for the stabilization of the DNA-binding surface of the p53 core domain and for the direct interaction of p53 with its DNA binding sites. These results predict that the vast majority of TP53 mutations leading to cancer do so in a dominant-negative fashion.
Brachmann
R K
RK
Department of Molecular Biology and Genetics, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA.
Vidal
M
M
Boeke
J D
JD
D000595:Amino Acid Sequence; D001483:Base Sequence; D015153:Blotting, Western; D003001:Cloning, Molecular; D003062:Codon; D005799:Genes, Dominant; D016158:Genes, p53; D005838:Genotype; D006801:Humans; D008969:Molecular Sequence Data; D009369:Neoplasms / Q000235:genetics*; D010641:Phenotype; D010957:Plasmids; D017354:Point Mutation; D012441:Saccharomyces cerevisiae / Q000235:genetics*; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis* / Q000302:isolation & purification
D003062:Codon; D016159:Tumor Suppressor Protein p53